Glenmark Pharmaceuticals Inc., USA Launches Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals Inc., USA has launched Vancomycin Hydrochloride for Injection USP in two strengths (500 mg/vial and 1 g/vial). The generic drug is bioequivalent and therapeutically equivalent to the reference listed drug of Fresenius Kabi USA, LLC. According to IQVIA sales data for the 12-month period ending March 2026, this injectable antibiotic market achieved annual sales of approximately $37.9 million in the US. The launch expands Glenmark's injectable portfolio in North America and supports the company's strategy of providing affordable generic medicines. Marc Kikuchi, President & Business Head, North America, called it a continued commitment to expanding access to quality, affordable medicines in the US.
The launch strengthens Glenmark's US generics portfolio with a product in the ~$38 million annual injectables market. While it adds a new revenue stream, the actual financial contribution will depend on market share capture in a competitive generic space.